What Femodene treats: main uses and benefits

Femodene is a combined oral contraceptive pill, often referred to as 'the Pill.' It contains two types of female hormones: an estrogen (ethinylestradiol) and a progestogen (gestodene). These hormones work together to provide effective protection against pregnancy.

Primary Use: Contraception

The main purpose of Femodene is to prevent pregnancy. It achieves this through three primary mechanisms:

• Inhibiting Ovulation: The hormones prevent an egg from being released from the ovaries each month.
• Altering Cervical Mucus: It increases the thickness of the fluid at the neck of the womb, making it more difficult for sperm to enter and reach an egg.
• Thinning the Uterine Lining: It changes the lining of the womb so that it is less likely to accept a fertilized egg.

Additional Benefits

Beyond its use as a contraceptive, many individuals are prescribed Femodene because it can help manage various menstrual-related concerns. These benefits may include:

• Cycle Regulation: It can help establish a more regular and predictable monthly menstrual cycle.
• Reduction in Menstrual Symptoms: The use of Femodene often results in lighter and less painful periods. It may also alleviate some symptoms associated with premenstrual syndrome (PMS).
• Management of Endometriosis: In some cases, the hormones in Femodene can help manage the symptoms of conditions such as endometriosis by suppressing the cyclic growth of the uterine lining.

Population Eligibility and Contraindications

The official regulatory profile for Femodene strictly defines eligibility based on a patient's medical history and current physiological status. The medicine is indicated for use by women of reproductive potential following menarche.

Contraindications (Must Not Use)

Femodene is absolutely contraindicated for women with a current or history of venous or arterial thromboembolism (such as DVT, stroke, or heart attack) or those with known thrombophilias (blood clotting disorders). Use is also prohibited for women over age 35 who smoke. Further contraindications include a history of migraine with focal neurological symptoms, severe hepatic disease or liver tumours, uncontrolled hypertension, severe diabetes with vascular damage, and known or suspected pregnancy.

Restrictions and Limitations

Use is not indicated after menopause. The medication must be temporarily discontinued at least four weeks prior to elective major surgery or prolonged immobilization, and should not be resumed until two weeks after full mobility is restored. Femodene is not recommended during lactation or breastfeeding.

Interactions with other medicines and products

Femodene's interaction profile is strictly defined by regulatory documents, focusing on agents that alter the concentration of its hormones or pose a risk of liver enzyme elevation. This section summarizes official interaction statements.

Contraindicated Combinations

Specific Hepatitis C (HCV) direct-acting antiviral regimens are officially contraindicated for co-administration. These include medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir. This restriction is due to the documented risk of elevated liver enzyme levels (ALT elevations).

Pharmacokinetic and Absorption Interactions

Interaction Type	Interacting Agent or Condition	Official Regulatory Outcome
Efficacy Reduction	Enzyme-Inducing Drugs (e.g., CYP3A4 inducers)	Leads to increased clearance of contraceptive hormones, resulting in reduced contraceptive effectiveness for pregnancy prevention.
Drug Exposure Increase	Etoricoxib	Has been officially documented to increase the exposure (plasma concentrations) of Ethinyl Estradiol.
Effect on Other Drugs	Lamotrigine	Causes a reduction in Lamotrigine plasma concentrations via induction of glucuronidation, a documented pharmacodynamic interaction.
Absorption Interference	Gastro-intestinal upset (vomiting/diarrhoea)	If occurring within 4 hours of tablet-taking, it may officially reduce efficacy due to incomplete hormone absorption, requiring supplementary precautions.

How Femodene Works

Central Suppression of the Reproductive Cycle

This domain involves the active ingredients, ethinylestradiol (estrogen) and gestodene (progestogen), acting as agonists on hormone receptors in the brain's control centers. By mimicking high hormone levels, the drug triggers a powerful negative feedback loop. This systemic signal suppresses the surge of hormones that normally trigger egg maturation and release, thereby causing the primary physiological effect of anovulation (inhibiting egg release).

---

Creation of Peripheral Physiological Barriers

The progestogen component, gestodene, targets the tissues of the reproductive tract, establishing supplementary effects. It causes the endometrium (womb lining) to thin, reducing its receptivity. Concurrently, it thickens the cervical mucus, creating a physical barrier that restricts the movement of sperm. These localized alterations provide two additional, distinct layers of mechanistic action.

Administration Guidelines: Femodene

The use of Femodene follows a cyclic daily regimen for this combined oral contraceptive. Administration is based on the oral route for systemic delivery of the active ingredients, 30 micrograms Ethinyl Estradiol and 75 micrograms Gestodene.

Feature	Administration Guideline
Route of Administration	The medication is taken orally as a coated tablet, which must be swallowed whole with water.
Dosing Schedule	One active tablet is taken daily for 21 consecutive days. This is followed by a 7-day tablet-free interval (or 7 inactive tablets in an ED pack) before beginning the next pack.
Timing Constraint	Each tablet must be taken at about the same time each day to ensure a consistent 24-hour interval between doses. Administration is generally permitted without regard to meals.
Missed-Dose Rule	If the administration of a tablet is delayed by more than 12 hours from the usual time, the level of protection may be reduced. Specific instructions, including the potential use of additional non-hormonal contraception for seven days, must then be followed.
Post-Partum Use	Starting the medication 21 days after delivery may be permitted, provided the patient is fully mobile and without complications, but a healthcare provider should be consulted for proper timing.

The prescribed protocol dictates a daily dosing frequency that adheres to a 21-day cycle, creating a structure for maintaining the intended pharmaceutical profile. Consistent timing and specific procedures for handling missed doses are the primary procedural constraints for use.

Femodene: Recent Clinical Evidence

---

Evidence for Use in Pregnancy Prevention (Contraception)

The research base for this combined hormonal product includes large-scale Randomized Controlled Trials (RCTs) and extensive Post-Marketing Observational Studies involving women of reproductive age. These trials research examined how the frequency of pregnancies was measured, a metric often summarized using the Pearl Index (failure rate measurement). Researchers also studies monitored changes in expected cycle regularity and usage patterns over extended periods. Studies reported measurements of annualized pregnancy rates within the observed populations in clinical settings, and these findings evidence contributes to understanding symptom patterns observed in the studies.

Evidence for Symptom Management and Research Gaps

Clinical research has explored the role of this combined hormonal product in managing specific outcomes related to systemic or functional imbalance. For moderate acne vulgaris, studies describe changes measured in lesion counts and physician ratings. Trials also studies report how symptoms evolved in populations presenting with severe menstrual cramps (dysmenorrhea) and excessive menstrual bleeding (menorrhagia), assessing the evolution of pain scores and blood loss volume measurements.

Key Limitations and Uncertainty: Evidence is limited in fully translating controlled trial efficacy to real-world outcomes where adherence and compliance are variables. Research concerning Endometriosis and Polycystic Ovary Syndrome (PCOS) symptom support evidence is limited and findings were mixed in some studies. Data for certain groups remain insufficient, particularly in patients with complex comorbidities, and long-term effects are not fully established compared to all newer contraceptive methods.

Key Studies & References Combined hormonal contraceptives for acne (Cochrane Review CD000194)

Common questions about Femodene (FAQ)

Q: What is Femodene and how is it used?

A: Femodene is a combined oral contraceptive pill that contains two active ingredients: the estrogen ethinylestradiol and the progestogen gestodene. It is used primarily to prevent pregnancy.

Q: How does Femodene work to prevent pregnancy?

A: The two hormones in Femodene work together through several mechanisms. They primarily prevent the release of an egg from the ovaries (ovulation). They also cause changes to the fluid in the cervix, making it more difficult for sperm to reach the egg, and alter the lining of the womb to make it less receptive to a fertilized egg.

Q: What should I do if I miss a dose of Femodene?

A: If a dose is missed, it is advised to consult the patient information leaflet provided with the medication or seek guidance from a healthcare professional regarding the specific instructions on when to take the missed pill and if additional contraceptive methods are needed. Do not rely on this section for medical instruction.

Q: Are there any common side effects associated with Femodene?

A: Like all medicines, Femodene may be associated with side effects, although not everyone experiences them. Common reported effects may include headaches, nausea, changes in mood, and breast tenderness. The frequency and severity of side effects vary among individuals.

Q: Who should not take Femodene?

A: The use of Femodene is not suitable for everyone. Individuals with certain medical conditions, such as a history of blood clots, certain types of cancer, or unexplained vaginal bleeding, are generally advised not to use it. A healthcare professional can determine if Femodene is appropriate for a patient's individual health profile.

How to Store and Dispose of Femodene?

Official regulatory documents define specific requirements for storing and disposing of this medicine to ensure its stability and manage waste responsibly.

Storage Conditions

Femodene must be stored under controlled conditions. The product must not be stored above 25 C and must be protected from light. Keeping the medicine in its original packaging helps maintain these conditions. The stated shelf life is 5 years.

Storage Constraint	Requirement
Maximum Temperature	Do not store above 25 C
Light Protection	Protect from light (keep in original container)

Disposal Instructions

Disposal must adhere to local requirements. Any unused product or waste material should be disposed of in accordance with local requirements for pharmaceuticals. It is strictly prohibited to dispose of this medicine via wastewater or household waste, as the product may pose a risk to the aquatic environment.